RecruitingNot ApplicableNCT03853915

FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)

Sponsor

University Health Network, Toronto

Enrollment

64 participants

Start Date

Apr 23, 2019

Study Type

INTERVENTIONAL

Conditions

Cervical Cancer

Summary

Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer. The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using two types of monitoring — a PET scan to measure tumor activity, and a blood test to detect HPV (a virus that causes cervical cancer) circulating in the blood — during and after chemoradiation treatment for cervical cancer, to see if these tools can predict how well the treatment is working. **You may be eligible if...** - You are 18 or older - You have been diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix (confirmed by biopsy), FIGO stage IB through IVA - You are scheduled to receive radical radiation therapy combined with cisplatin chemotherapy as your primary treatment **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body beyond what can be treated with radiation - You have already received any cancer treatment for your cervical cancer - Your tumor is a rare type (such as small cell) that is not covered by the study criteria - You have contraindications to PET scanning, radiation, or chemotherapy (such as severe kidney failure) - You are pregnant or breastfeeding - You have had another invasive cancer in the last 5 years (with exceptions for certain skin cancers) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST[18-F]- FDG - PET

\[F-18\]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, \[F-18\]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.